Abstract:Fibroblast growth factor receptors (FGFRs), overexpressed on the surface of a variety of tumor cells and on tumor neovasculature in situ, are potential targets for tumor- and vascular-targeting therapy. This study aimed to develop a FGFR-mediated drug delivery system to target chemotherapeutic agents to FGFR-overexpressed tumor cells and tumor neovasculature endothelial cells in vitro and in vivo. Here we designed a truncated human basic fibroblast growth factor peptide (tbFGF), which was attached to the surface of cationic liposomal doxorubicin (LPs-DOX) and paclitaxel (LPs-PTX) via electrostatic force. Then we characterized the tbFGF-modified liposome (tbFGF-LPs) and examined internalization of doxorubicin in tumor cells (TRAMP-C1, B16) and HUVEC cells in vitro. In vivo, we evaluated the biodistribution and antitumor efficacy of tbFGF-LPs-DOX and tbFGF-LPs-PTX in C57BL/6J mice bearing TRAMP-C1 prostate carcinoma and B16 melanoma, respectively. The tbFGF-LPs-DOX significantly improved the uptake of doxorubicin in TRAMP-C1, B16 and HUVEC cells, respectively. Biodistribution study in B16 tumor-bearing mice showed that tbFGF-LPs-PTX achieved 7.1-fold (72.827±7.321mgh/L vs 10.292±0.775mgh/L, mean±SD, P<0.01) accumulation of paclitaxel in tumor tissue than those of free paclitaxel. More importantly, treatment of tumor-bearing mice with tbFGF-LPs-DOX and tbFGF-LPs-PTX showed the significant inhibition in tumor growth and improvement in survival rate as compared with mice treated with free and liposomal drugs in TRAMP-C1 and B16 tumor models, respectively. Furthermore, repeated intravenous administration of tbFGF-LPs-DOX/PTX did not induce anti-bFGF antibodies. These results suggested that this FGFR-mediated drug delivery system may provide a new treatment strategy for tumors which overexpress FGFRs.

Expression, Purification of a Synthetic Fuse-Protein-tsf from PF4 and TSP1 Fragments and Its Effect on Angio-Genesis and Tumor Growth

Irreversible Inhibition of Nuclear Exoribonuclease by Thymidine-3'-Fluorophosphate and p-Haloacetamidophenyl Nucleotides

Pathological Expression of Tissue Factor Confers Promising Antitumor Response to A Novel Therapeutic Antibody Sc1 in Triple Negative Breast Cancer and Pancreatic Adenocarcinoma

Metabonomic Investigation of Biological Effects of a New Vessel Target Protein Ttf-Phlip in a Mouse Model.

A Novel Anti-Tissue Factor Monoclonal Antibody with Anticoagulant Potency Derived from Synthesized Multiple Antigenic Peptide Through Blocking FX Combination with TF

Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo.

In Vitro Biological Activities of Transmembrane Superantigen Staphylococcal Enterotoxin A Fusion Protein

A Tissue Factor Targeted Nanomedical System for Thrombi-Specific Drug Delivery.

Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction

A Tissue Factor-Cascade-targeted Strategy to Tumor Vasculature: a Combination of EGFP-EGF1 Conjugation Nanoparticles with Photodynamic Therapy.

Improved Tumor-Targeting Drug Delivery and Therapeutic Efficacy by Cationic Liposome Modified with Truncated Bfgf Peptide.

Small brown planthopper resistance loci in wild rice (Oryzaofficinalis)

Expression, Purification, and Characterization of A Novel Recombinant Fusion Protein, Rhtpo/Scf, in Escherichia Coli

Production of Extracellular Domain of Human Tissue Factor Using Maltose-Binding Protein Fusion System.

Expression, Refolding, and Characterization of Recombinant Thrombopoietin/stem Cell Factor Fusion Protein in Escherichia Coli

Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability.

Cloning, Expression and Biological Characterization of Htfpi-2 Gene

Detection of Biological Activity of Recombinant Human Tumor Necrosis Factor α Inhibitory Peptide Fused with Anti-Inflammatory Acidic Tail

A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer

Tissue Factor Overexpression in Triple-Negative Breast Cancer Promotes Immune Evasion by Impeding T-cell Infiltration and Effector Function.

The Effect Of Human Tissue Factor Pathway Inhibitor-2 On The Growth And Metastasis Of Fibrosarcoma Tumors In Athymic Mice